featured
Efficacy of Neratinib Plus Ado-Trastuzumab Emtansine for Pretreated and Untreated HER2+ Breast Cancer Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Ann. Oncol 2024 Nov 01;35(11)993-1002, RA Freedman, HM Heiling, T Li, D Trapani, N Tayob, KL Smith, R Davis, AM Pereslete, MK DeMeo, C Cotter, WY Chen, HA Parsons, CA Santa-Maria, C Van Poznak, B Moy, AM Brufsky, ME Melisko, CC O'Sullivan, N Ashai, Y Rauf, JR Nangia, RT Burns, J Savoie, AC Wolff, EP Winer, MF Rimawi, IE Krop, NU LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.